### Analysis:

Merck & Co.'s Q2 2016 earnings call revealed a mixed bag of results. The company reported a 1% year-over-year increase in total revenues, driven by strong performances in human health and animal health businesses. However, there were notable challenges, such as lower contributions from the revenue hedge program and third-party manufacturing sales. Additionally, the company experienced a $210 million headwind in sales due to a scaling back of operations in Venezuela.

The company's guidance for the full year was revised to reflect a more conservative estimate, with revenues expected to be $39.1 billion to $40.1 billion, including a 2% negative impact from foreign exchange. Non-GAAP gross margin and operating expenses also showed modest improvements, with a 30 basis point increase in gross margin and a 4% increase in operating expenses.

The call highlighted Merck's focus on innovation and strategic partnerships, with notable developments in the development of KEYTRUDA and ZEPATIER. However, the company also acknowledged the challenges posed by competition and the need to adapt to changing market dynamics.

### Conclusion:

The Q2 2016 earnings call for Merck & Co. provided a mixed outlook, with the company reporting modest revenue growth and a more conservative full-year guidance. The stock is likely to face short-term pressure due to tempered guidance and the ongoing challenges in the market. However, the company's focus on innovation and strategic partnerships suggests long-term potential.

### Rating:

-1